Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

Anomalous patterns of brain gyrification have been reported in major psychiatric disorders,
presumably reflecting their neurodevelopmental pathology. However, previous reports …

Importance Schizophrenia is associated with alterations in mean regional brain volumes.
However, it is not known whether the clinical heterogeneity seen in the disorder is reflected …

Primary and persistent negative symptoms (PPNS) represent an unmet need in the care of
people with schizophrenia. They have an unfavourable impact on real-life functioning and …

BackgroundMost studies suggested that patients with deficit schizophrenia have more
severe impairment compared with patients with non-deficit schizophrenia. However, it is not …

We previously proposed that people with schizophrenia who have primary, enduring
negative symptoms have a disease—deficit schizophrenia (DS)—that is separate from that …

Background It has been hypothesized that dopamine function in schizophrenia exhibits
heterogeneity in excess of that seen in the general population. However, no previous study …

Objective Negative symptoms of schizophrenia are substantially disabling and treatment
resistant. Novel treatments like repetitive transcranial magnetic stimulation (TMS) need to be …

Introduction: Bipolar disorder (BD) is a chronic psychiatric disorder marked by clinical and
pathophysiological heterogeneity. There is a high expectation that personalized approaches …

Background Deficits in neurocognition and social cognition are drivers of reduced
functioning in schizophrenia spectrum disorders, with potentially shared neurobiological …